Leopoldina
Nationale Akademie
der Wissenschaften

Curriculum Vitae Professor Dr. Holger Moch

Name: **Holger Moch**
Born: **9 February 1962**

Major Scientific Interests: Biomarkers in cancer, Pathology of uropathological and gynecologic tumors

Academic and Professional Career

since 2010	Director, Medical Division Pathology and Laboratory Medicine, University Hospital Zurich, Switzerland
since 2004	Full Professor of Pathology University Zurich, Chairman, Institute for Pathology, University Hospital Zurich, Switzerland
2001	Associate Professor of Pathology (Titularprofessor), University Basel, Switzerland
1998	Habilitation, University Basel, Switzerland
1988	Ph.D., Humboldt University Berlin, Germany
1982 - 1988	Studies, Humboldt University Berlin, Germany

Functions in Scientific Societies and Committees

since 2009	Secretary-Treasurer, German Society for Pathology
since 2007	Member; Kantonal-Züricherische Krebskommission
since 2006	Advisory Board; Charles Rodolphe Brupbacher Foundation (Organizer 2007 / 2009 Symposium of the CRB Foundation)

since 2005 Member Scientific Committee; Swiss Cancer League and Oncosuisse

2004 - 2010 Swiss Society for Pathology, Executive Committee

2004 - 2010 Executive Committee; Swiss Group for Clinical Cancer Research (SAKK)

Honours and Awarded Memberships

since 2014 Member of the Swiss Academy of Medical Sciences (SAMW)

since 2007 Member of the German National Academy of Sciences Leopoldina

2004 Fellow of the International Society of Uropathology

Major Scientific Interests

Holger Moch has contributed to the molecular characterization of cancer. The major goal of his research is the identification of clinically significant biomarkers for the prediction of prognosis and response to therapy. He made major contributions in uropathology and gynecopathology.

The majority of his studies were performed at the Institute of Pathology of the University Basle and at the Institute of Surgical Pathology of the University Zurich. The current research interests are focused on the relevance of the von Hippel-Lindau protein for renal carcinoma initiation and metastases. His research led to a molecular progression model of renal cancer. A second research interest is related to the characterization of “differentiation-“ and “Cancer testis-antigens” in solid tumors. Novel molecular high throughput technologies, e.g. comparative genomic hybridization, fluorescence and in situ hybridization and expression array analyses are tested for their potential in diagnostic pathology.